| 前收市價 | 3.9000 |
| 開市 | 3.7000 |
| 買盤 | 2.5000 |
| 賣出價 | 2.7500 |
| 拍板 | 325.00 |
| 到期日 | 2024-06-21 |
| 今日波幅 | 2.3700 - 3.7000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 1.22k |
ZacksAmgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
Zacks4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly
Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this space.
Motley FoolMeet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Could Amgen be the next stock to soar due to a GLP-1 drug?
